Benzinga | Feb 25, 2021 07:34AM EST

Biocryst Pharmaceuticals Q4 EPS $(0.34) Misses $(0.25) Estimate, Sales $4.02M Miss $17.52M Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.25) by 36 percent. This is a 1600 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $4.02 million which missed the analyst consensus estimate of $17.52 million by 77.08 percent. This is a 89.89 percent decrease over sales of $39.73 million the same period last year.